Skip to main content
Erschienen in: Lung 3/2016

31.03.2016

Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure

verfasst von: Melike Demir, Halide Kaya, Mahsuk Taylan, Aysun Ekinci, Sureyya Yılmaz, Fatma Teke, Cengizhan Sezgi, Abdullah Cetin Tanrikulu, Fatih Meteroglu, Abdurrahman Senyigit

Erschienen in: Lung | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The purpose of this study was to investigate the potential value of certain biomarkers in predicting the presence of malignant pleural mesothelioma (MPM) in individuals environmentally exposed to asbestos.

Methods

This prospective study investigated three groups; a control group composed of 41 healthy subjects, an asbestos exposure group consisting of 48 individuals, and a MPM group consisting of 42 patients. Serum levels of soluble mesothelin-related peptide (SMRP), thioredoxin-1 (TRX), epidermal growth factor receptor (EGFR), fibulin-3, syndecan-1 (SDC-1), and mesothelin were determined.

Results

Benign pleural plaques were present in 27 (58.3 %) of the individuals in the asbestos exposure group. The asbestos exposure group had significantly higher mean TRX, SMRP, and mesothelin levels compared to the control group (p = 0.023, p = 0.011, and p < 0.001, respectively). Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002). Unlike the other biomarkers, SMRP and TRX levels increased in a graded fashion among the control, asbestos exposure, and MPM groups, respectively. Area under the curve values for SMRP and TRX were 0.86 and 0.72, respectively (95 % CI 0.79–0.92 and p < 0.001 for SMRP, and 95 % CI 0.62–0.81 and p < 0.001 for TRX). The cut-off value for SMRP was 0.62 nmol/l (sensitivity: 97.6 %, specificity: 68.9 %, positive predictive value (PPV): 56.2 %, and negative predictive value (NPV): 98.3 %) and for TRX was 156.67 ng/ml (sensitivity: 92.9 %, specificity: 77.6 %, PPV: 41.4 %, and NPV: 92.1 %). The combination of the biomarkers reached a sensitivity of 100 %, but had lower specificity (as high as 27.7 %).

Conclusions

Serum biomarkers may be helpful for early diagnosis of MPM in asbestos-exposed cases. SMRP and TRX increased in a graded fashion from the controls to asbestos exposure and MPM groups. These two seem to be the most valuable biomarkers for the diagnosis of MPM, both individually and in combination.
Literatur
1.
Zurück zum Zitat Bayram M, Dongel I, Akbas A, Benli I, Akkoyunlu ME, Bakan ND (2014) Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung 192(1):197–203CrossRefPubMed Bayram M, Dongel I, Akbas A, Benli I, Akkoyunlu ME, Bakan ND (2014) Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung 192(1):197–203CrossRefPubMed
2.
Zurück zum Zitat Santarelli L, Staffolani S, Strafella E et al (2015) Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer 90(3):457–464CrossRefPubMed Santarelli L, Staffolani S, Strafella E et al (2015) Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer 90(3):457–464CrossRefPubMed
3.
Zurück zum Zitat Maeda M, Hino O (2006) Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 56(11):649–654CrossRefPubMed Maeda M, Hino O (2006) Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 56(11):649–654CrossRefPubMed
4.
Zurück zum Zitat Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I (2005) Soluble mesothelin-related protein—a blood test for mesothelioma. Lung Cancer 49(Suppl 1):S109–S111CrossRefPubMed Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I (2005) Soluble mesothelin-related protein—a blood test for mesothelioma. Lung Cancer 49(Suppl 1):S109–S111CrossRefPubMed
5.
Zurück zum Zitat Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 49(10):1721–1726CrossRefPubMed Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 49(10):1721–1726CrossRefPubMed
6.
Zurück zum Zitat Canessa PA, Franceschini MC, Ferro P et al (2013) Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest 31(1):43–50CrossRefPubMed Canessa PA, Franceschini MC, Ferro P et al (2013) Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest 31(1):43–50CrossRefPubMed
7.
Zurück zum Zitat Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D et al (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18(2):646–650CrossRefPubMed Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D et al (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18(2):646–650CrossRefPubMed
8.
Zurück zum Zitat Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31–39CrossRefPubMed Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31–39CrossRefPubMed
9.
Zurück zum Zitat Schildgen V, Pabst O, Tillmann RL et al (2015) Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany. Appl Immunohistochem Mol Morphol 23(2):118–125CrossRefPubMed Schildgen V, Pabst O, Tillmann RL et al (2015) Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany. Appl Immunohistochem Mol Morphol 23(2):118–125CrossRefPubMed
10.
Zurück zum Zitat Gaafar R, Bahnassy A, Abdelsalam I et al (2010) Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 70(1):43–50CrossRefPubMed Gaafar R, Bahnassy A, Abdelsalam I et al (2010) Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 70(1):43–50CrossRefPubMed
13.
Zurück zum Zitat Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K (2014) Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int 2014:419853CrossRefPubMedPubMedCentral Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K (2014) Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int 2014:419853CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Todosi AM, Gavrilescu MM, Anitei GM, Filip B, Scripcariu V (2012) Colon cancer at the molecular level–usefulness of epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med Nat Iasi 116(4):1106–1111PubMed Todosi AM, Gavrilescu MM, Anitei GM, Filip B, Scripcariu V (2012) Colon cancer at the molecular level–usefulness of epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med Nat Iasi 116(4):1106–1111PubMed
15.
Zurück zum Zitat Zong F, Fthenou E, Mundt F et al (2011) Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PLoS ONE 6(6):e14816CrossRefPubMedPubMedCentral Zong F, Fthenou E, Mundt F et al (2011) Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PLoS ONE 6(6):e14816CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Sezgi C, Taylan M, Sen HS et al (2014) Oxidative status and acute phase reactants in patients with environmental asbestos exposure and mesothelioma. Sci World J 2014:902748CrossRef Sezgi C, Taylan M, Sen HS et al (2014) Oxidative status and acute phase reactants in patients with environmental asbestos exposure and mesothelioma. Sci World J 2014:902748CrossRef
17.
Zurück zum Zitat Cunningham GM, Roman MG, Flores LC et al (2015) The paradoxical role of thioredoxin on oxidative stress and aging. Arch Biochem Biophys 576:32–38CrossRefPubMed Cunningham GM, Roman MG, Flores LC et al (2015) The paradoxical role of thioredoxin on oxidative stress and aging. Arch Biochem Biophys 576:32–38CrossRefPubMed
18.
Zurück zum Zitat Tabata C, Terada T, Tabata R et al (2013) Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 47(1):e7–e11CrossRefPubMed Tabata C, Terada T, Tabata R et al (2013) Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 47(1):e7–e11CrossRefPubMed
19.
Zurück zum Zitat Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958–2970PubMed Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958–2970PubMed
20.
Zurück zum Zitat Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277(2):301–308CrossRefPubMed Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277(2):301–308CrossRefPubMed
21.
Zurück zum Zitat Trupiano JK, Geisinger KR, Willingham MC et al (2004) Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 17(4):476–481CrossRefPubMed Trupiano JK, Geisinger KR, Willingham MC et al (2004) Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 17(4):476–481CrossRefPubMed
22.
Zurück zum Zitat Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A (2015) Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol Oncol 49(3):279–285CrossRefPubMedPubMedCentral Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A (2015) Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol Oncol 49(3):279–285CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kaya H, Demir M, Taylan M et al (2015) Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 16(4):1403–1407CrossRefPubMed Kaya H, Demir M, Taylan M et al (2015) Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 16(4):1403–1407CrossRefPubMed
24.
25.
Zurück zum Zitat Saunders S, Jalkanen M, O’Farrell S, Bernfield M (1989) Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 108(4):1547–1556CrossRefPubMed Saunders S, Jalkanen M, O’Farrell S, Bernfield M (1989) Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 108(4):1547–1556CrossRefPubMed
26.
Zurück zum Zitat Orosz Z, Kopper L (2001) Syndecan-1 expression in different soft tissue tumours. Anticancer Res 21(1):733–737PubMed Orosz Z, Kopper L (2001) Syndecan-1 expression in different soft tissue tumours. Anticancer Res 21(1):733–737PubMed
27.
Zurück zum Zitat Kumar-Singh S, Jacobs W, Dhaene K et al (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186(3):300–305CrossRefPubMed Kumar-Singh S, Jacobs W, Dhaene K et al (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186(3):300–305CrossRefPubMed
28.
Zurück zum Zitat Szatmari T, Dobra K (2013) The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol 3:310CrossRefPubMedPubMedCentral Szatmari T, Dobra K (2013) The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol 3:310CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Metintas M, Metintas S, Ak G et al (2008) Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology 13(1):117–121CrossRefPubMed Metintas M, Metintas S, Ak G et al (2008) Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology 13(1):117–121CrossRefPubMed
30.
Zurück zum Zitat Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT (2002) Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 26(2):55–65CrossRefPubMed Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT (2002) Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 26(2):55–65CrossRefPubMed
31.
Zurück zum Zitat Kamp DW, Israbian VA, Preusen SE, Zhang CX, Weitzman SA (1995) Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am J Physiol 268(3 Pt 1):L471–L480PubMed Kamp DW, Israbian VA, Preusen SE, Zhang CX, Weitzman SA (1995) Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am J Physiol 268(3 Pt 1):L471–L480PubMed
32.
Zurück zum Zitat Metintas M, Ozdemir N, Solak M et al (1994) Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions. Respiration 61(6):330–335CrossRefPubMed Metintas M, Ozdemir N, Solak M et al (1994) Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions. Respiration 61(6):330–335CrossRefPubMed
33.
Zurück zum Zitat Tomasetti M, Amati M, Nocchi L et al (2011) Asbestos exposure affects poly (ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis. Mutagenesis 26(5):585–591CrossRefPubMed Tomasetti M, Amati M, Nocchi L et al (2011) Asbestos exposure affects poly (ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis. Mutagenesis 26(5):585–591CrossRefPubMed
34.
Zurück zum Zitat Pelclova D, Fenclova Z, Kacer P, Kuzma M, Navratil T, Lebedova J (2008) Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure. Ind Health 46(5):484–489CrossRefPubMed Pelclova D, Fenclova Z, Kacer P, Kuzma M, Navratil T, Lebedova J (2008) Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure. Ind Health 46(5):484–489CrossRefPubMed
35.
Zurück zum Zitat Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 30:421–455CrossRefPubMed Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 30:421–455CrossRefPubMed
36.
Zurück zum Zitat Thompson JK, Westbom CM, MacPherson MB et al (2014) Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. Part Fibre Toxicol 11:24CrossRefPubMedPubMedCentral Thompson JK, Westbom CM, MacPherson MB et al (2014) Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. Part Fibre Toxicol 11:24CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH (2010) Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 48(6):869–874CrossRefPubMed Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH (2010) Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 48(6):869–874CrossRefPubMed
38.
Zurück zum Zitat Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ (2014) Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 4(2):e004145CrossRefPubMedPubMedCentral Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ (2014) Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 4(2):e004145CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Hollevoet K, Reitsma JB, Creaney J et al (2012) Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 30(13):1541–1549CrossRefPubMedPubMedCentral Hollevoet K, Reitsma JB, Creaney J et al (2012) Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 30(13):1541–1549CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Scherpereel A, Grigoriu B, Conti M et al (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173(10):1155–1160CrossRefPubMed Scherpereel A, Grigoriu B, Conti M et al (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173(10):1155–1160CrossRefPubMed
41.
Zurück zum Zitat Fukuoka K, Kuribayashi K, Yamada S, Tamura K, Tabata C, Nakano T (2013) Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. Mol Clin Oncol 1(6):942–948PubMedPubMedCentral Fukuoka K, Kuribayashi K, Yamada S, Tamura K, Tabata C, Nakano T (2013) Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. Mol Clin Oncol 1(6):942–948PubMedPubMedCentral
42.
Zurück zum Zitat Cristaudo A, Bonotti A, Simonini S et al (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6(9):1587–1593CrossRefPubMed Cristaudo A, Bonotti A, Simonini S et al (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6(9):1587–1593CrossRefPubMed
Metadaten
Titel
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
verfasst von
Melike Demir
Halide Kaya
Mahsuk Taylan
Aysun Ekinci
Sureyya Yılmaz
Fatma Teke
Cengizhan Sezgi
Abdullah Cetin Tanrikulu
Fatih Meteroglu
Abdurrahman Senyigit
Publikationsdatum
31.03.2016
Verlag
Springer US
Erschienen in
Lung / Ausgabe 3/2016
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9868-1

Weitere Artikel der Ausgabe 3/2016

Lung 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.